Please assess the completion status of the following clinical trial:

Trial Title: A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be 18 years old at the time the informed consent form is signed~* Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate~* Be surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL (1.73 nM)~* Experienced disease progression after having received at least 1 but no more than 2 prior next-generation androgen receptor-targeted therapies, and 1 prior taxane-based chemotherapy, for castration-resistant disease~* Have a deleterious mutation in BRCA1/2 or ATM, or molecular evidence of other homologous recombination deficiency~Exclusion Criteria:~* Active second malignancy, with the exception of curatively treated non-melanoma skin cancer, carcinoma in situ, or superficial bladder cancer~* Prior treatment with any PARP inhibitor, mitoxantrone, cyclophosphamide or any platinum-based chemotherapy~* Symptomatic and/or untreated central nervous system metastases~* Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of rucaparib

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rucaparib (Type: EXPERIMENTAL): Oral rucaparib (monotherapy)

Based on this trial design, predict the completion outcome and termination type (if applicable).